292 related articles for article (PubMed ID: 2060581)
1. The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18).
Di Renzo L; Yefenof E; Klein E
Eur J Immunol; 1991 Jul; 21(7):1755-8. PubMed ID: 2060581
[TBL] [Abstract][Full Text] [Related]
2. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
[TBL] [Abstract][Full Text] [Related]
3. Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets.
Ramos OF; Patarroyo M; Yefenof E; Klein E
J Immunol; 1989 Jun; 142(11):4100-4. PubMed ID: 2565929
[TBL] [Abstract][Full Text] [Related]
4. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
5. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
Vetvicka V; Thornton BP; Ross GD
J Clin Invest; 1996 Jul; 98(1):50-61. PubMed ID: 8690804
[TBL] [Abstract][Full Text] [Related]
6. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
Thornton BP; Vĕtvicka V; Pitman M; Goldman RC; Ross GD
J Immunol; 1996 Feb; 156(3):1235-46. PubMed ID: 8558003
[TBL] [Abstract][Full Text] [Related]
8. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
Vetvicka V; Thornton BP; Wieman TJ; Ross GD
J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
[TBL] [Abstract][Full Text] [Related]
9. Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18).
Roubey RA; Ross GD; Merrill JT; Walton F; Reed W; Winchester RJ; Buyon JP
J Immunol; 1991 May; 146(10):3557-62. PubMed ID: 1673986
[TBL] [Abstract][Full Text] [Related]
10. Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells.
Klein E; Di Renzo L; Yefenof E
Mol Immunol; 1990 Dec; 27(12):1343-7. PubMed ID: 1980339
[TBL] [Abstract][Full Text] [Related]
11. Evidence for involvement of beta-glucan-binding cell surface lectins in human natural killer cell function.
Duan X; Ackerly M; Vivier E; Anderson P
Cell Immunol; 1994 Sep; 157(2):393-402. PubMed ID: 8069924
[TBL] [Abstract][Full Text] [Related]
12. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.
Vĕtvicka V; Hanikýrová M; Vĕtvicková J; Ross GD
Clin Exp Immunol; 1999 Feb; 115(2):229-35. PubMed ID: 9933447
[TBL] [Abstract][Full Text] [Related]
13. Beta-glucan affects leukocyte navigation in a complex chemotactic gradient.
Tsikitis VL; Albina JE; Reichner JS
Surgery; 2004 Aug; 136(2):384-9. PubMed ID: 15300205
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates.
Yefenof E; Benizri R; Reiter Y; Klein E; Fishelson Z
J Immunol; 1990 Feb; 144(4):1538-43. PubMed ID: 2303717
[TBL] [Abstract][Full Text] [Related]
15. CD11b and CD11c antigens are rapidly increased on human natural killer cells upon activation.
Werfel T; Witter W; Götze O
J Immunol; 1991 Oct; 147(7):2423-7. PubMed ID: 1680915
[TBL] [Abstract][Full Text] [Related]
16. CR3 (CD11b/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents.
Muto S; Vĕtvicka V; Ross GD
J Clin Immunol; 1993 May; 13(3):175-84. PubMed ID: 8100571
[TBL] [Abstract][Full Text] [Related]
17. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors.
Ramos OF; Kai C; Yefenof E; Klein E
J Immunol; 1988 Feb; 140(4):1239-43. PubMed ID: 2963864
[TBL] [Abstract][Full Text] [Related]
18. Generation of recombinant fragments of CD11b expressing the functional beta-glucan-binding lectin site of CR3 (CD11b/CD18).
Xia Y; Ross GD
J Immunol; 1999 Jun; 162(12):7285-93. PubMed ID: 10358177
[TBL] [Abstract][Full Text] [Related]
19. CD11b/CD18 integrin and a beta-glucan receptor act in concert to induce the synthesis of platelet-activating factor by monocytes.
Elstad MR; Parker CJ; Cowley FS; Wilcox LA; McIntyre TM; Prescott SM; Zimmerman GA
J Immunol; 1994 Jan; 152(1):220-30. PubMed ID: 7902855
[TBL] [Abstract][Full Text] [Related]
20. Identification of haptoglobin as an alternative ligand for CD11b/CD18.
El Ghmati SM; Van Hoeyveld EM; Van Strijp JG; Ceuppens JL; Stevens EA
J Immunol; 1996 Apr; 156(7):2542-52. PubMed ID: 8786317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
